TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15105105

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir at 800/200 mg BID (arm 1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir at 400/400 mg BID (arm 2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rifampin at 600 mg once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir combined with rifampin
Number of subjects: 32
Study: 10955700

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 200 microg daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 microg daily
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (100 or 200 microg daily)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 122
Study: 9101424

Group type: EXPERIMENTAL
Intervention: 4 g/day of an 85% concentrate of the ethyl esters of eicosapentenoic and docosahexaenoic acids for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: 4 g/day of ethyl esters of corn oil fatty acids
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4 g/day of an 85% concentrate of the ethyl esters of eicosapentenoic and docosahexaenoic acids
Number of subjects: 40
Study: 8267193

Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Flumazenil 1 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Flumazenil 3 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg and 3 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 72
Study: 2860156

Group type: EXPERIMENTAL
Intervention: Local, intra-operative administration of povidone-iodine
Number of subjects: 250

Group type: COMPARATOR
Intervention: Prophylactic antibiotic therapy
Number of subjects: 250
Study: 3113246

Group type: EXPERIMENTAL
Intervention: Misoprostol, 800 micrograms to 1,200 micrograms daily in four to six divided doses, for periods of from one day to 17 months.
Number of subjects: 157
Study: 31190495

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with penetrating moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Biological feedback training of pelvic floor muscle
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (EA + moxibustion and control)
Number of subjects: 60
Study: 27750353

Group type: EXPERIMENTAL
Intervention: Intensive diabetes screening and treatment program in Ward-A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment in Ward-B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients requiring percutaneous coronary intervention (PCI) in Ward-A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients without PCI in Ward-A
Number of subjects: 0
Study: 26173842

Group type: EXPERIMENTAL
Intervention: Internet-based brief intervention (IBI) consisting of normative feedback, feedback on consequences of alcohol use, calorific value of reported consumption, computed blood alcohol concentration for reported consumption, indication of risk, information on alcohol and health, recommendations indicating low-risk drinking limits.
Number of subjects: 737

Group type: COMPARATOR
Intervention: Control condition: no intervention (assessment only).
Number of subjects: 737
Study: 22911373

Group type: EXPERIMENTAL
Intervention: NMES + ERGO training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control + ERGO training
Number of subjects: 14
Study: 21998703

Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir
Number of subjects: 4758

Group type: EXPERIMENTAL
Intervention: Emtricitabine-tenofovir
Number of subjects: 4758

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 4758
Study: 17681994

Group type: EXPERIMENTAL
Intervention: Occupational health service consultation for high risk group (n = 209)
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Phone advice centre for intermediate risk group (n = 268)
Number of subjects: 1341
Study: 16435115

Group type: EXPERIMENTAL
Intervention: (11)C‐methionine PET/CT
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Subtotal parathyroidectomy
Number of subjects: 18
Study: 15050085

Group type: EXPERIMENTAL
Intervention: Combined psychotherapy and pharmacotherapy for depression
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Double depression (major depression plus dysthymia)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Frequency of heroin use
Number of subjects: 53
Study: 10652955

Group type: EXPERIMENTAL
Intervention: Pamidronate (APD) 30 mg i.v. in 500 ml D5W over 4 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pamidronate (APD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9284985

Group type: EXPERIMENTAL
Intervention: Active treatment with extracts of Dermatophagoides pteronyssinus (Dpt) or D. farinae (Dfa) (Alutard SQ, ALK, Denmark)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 31
Study: 8367775

Group type: EXPERIMENTAL
Intervention: Early reinfusion of autologous blood
Number of subjects: 57

Group type: COMPARATOR
Intervention: Delayed reinfusion of autologous blood
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Early reinfusion in A/P and PSF groups
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Early and delayed reinfusion groups
Number of subjects: 57
Study: 2875053

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 30099405

Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention (CTI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27074137

Group type: EXPERIMENTAL
Intervention: Wide-screen, high-definition (WSHD) monitors
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard monitors (SD)
Number of subjects: 152
Study: 24521021

Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 88

Group type: COMPARATOR
Intervention: calcineurin inhibitor
Number of subjects: 88
Study: 23750536

Group type: EXPERIMENTAL
Intervention: Glutamate supplement + carbohydrate drink (GLU+CHO)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glutamate supplement + placebo drink (GLU)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo supplement + carbohydrate drink (CHO)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo supplement + placebo drink (CON)
Number of subjects: 9
Study: 20510247

Group type: EXPERIMENTAL
Intervention: Balanced 6% HES 130/0.4 plus a balanced crystalloid (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unbalanced HES-in-saline plus saline (n = 30)
Number of subjects: 60
Study: 18609122

Group type: EXPERIMENTAL
Intervention: 50 mg ranitidine as a bolus intravenously
Number of subjects: 12

Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 12
Study: 16382112

Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin (TP)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Cyclophosphamide and cisplatin (CP)
Number of subjects: 680
Study: 14697932

Group type: EXPERIMENTAL
Intervention: Cap Arpimune ME (test formulation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cap Sandimmune Neoral (reference formulation)
Number of subjects: 30
Study: 10910856

Group type: EXPERIMENTAL
Intervention: 70 degrees tilt-up position (TUP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: horizontal posture
Number of subjects: 20
Study: 8738312

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Oxaprotiline
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: All active treatments
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 1200
Study: 1348396

Group type: EXPERIMENTAL
Intervention: 1% apraclonidine HCl
Number of subjects: 329

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 329
Study: 3924617

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin system (TNS) 20 cm2 or greater
Number of subjects: 56

Group type: COMPARATOR
Intervention: Transdermal nitroglycerin system (TNS) 10 cm2
Number of subjects: 56
Study: 30908082

Group type: EXPERIMENTAL
Intervention: 200 mg BI 653048
Number of subjects: 3

Group type: COMPARATOR
Intervention: 20 mg prednisolone
Number of subjects: 3
Study: 29954713

Group type: EXPERIMENTAL
Intervention: 3 weekly stage-tailored messages on healthful behaviors for 10 weeks; and 3 monthly stage-tailored messages and 1 monthly e-mail encouraging a visit to the portal page after the 3-month physical assessment
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 156
Study: 26784939

Group type: EXPERIMENTAL
Intervention: Talinolol 50 mg tablet (oral administration)
Number of subjects: 40
Study: 26016363

Group type: EXPERIMENTAL
Intervention: Ligustrazine treatment (80 mg/d; i.v.; for 2 weeks) in addition to standard treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard treatment with antibiotics, antiasthmatic and expectorant medications, and oxygenation
Number of subjects: 70
Study: 21862953

Group type: EXPERIMENTAL
Intervention: Combination therapy with intravitreal ranibizumab and topical bromfenac
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ranibizumab alone
Number of subjects: 30
Study: 19668346

Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (MHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17599879

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 144
Study: 15177709

Group type: EXPERIMENTAL
Intervention: Subjects who had recently fallen in love
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Subjects who had recently fallen in love (men)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Subjects who had recently fallen in love (women)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Subjects who were single or in a long-lasting relationship
Number of subjects: 24

Group type: COMPARATOR
Intervention: Subjects who were single or in a long-lasting relationship (men)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Subjects who were single or in a long-lasting relationship (women)
Number of subjects: 24
Study: 11125353

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (InterStim system)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group (delayed implantation for 6 months)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Temporary inactivation of sacral nerve stimulation therapy
Number of subjects: 177
Study: 9743652

Group type: EXPERIMENTAL
Intervention: Combination Treatment (TPs and scanner technique)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Trigger points technique
Number of subjects: 324

Group type: COMPARATOR
Intervention: Scanner technique
Number of subjects: 324
Study: 8170098

Group type: EXPERIMENTAL
Intervention: Peribulbar anesthesia (PERI) with 6, 8 or 10 ml of bupivacaine-lidocaine-hyaluronidase mixture
Number of subjects: 160

Group type: COMPARATOR
Intervention: Retrobulbar anesthesia (RETRO) using Unsold technique with 5 ml of bupivacaine-lidocaine-hyaluronidase mixture and Nadbath/Rehman facial nerve block (5 ml etidocaine-lidocaine mixture)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All methods of anesthesia (including both PERI and RETRO)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: RETRO and PERI
Number of subjects: 160
Study: 2972897

Group type: EXPERIMENTAL
Intervention: oestradiol valerate/cyproterone acetate (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: oestradiol valerate/norethisterone (Group B)
Number of subjects: 50
Study: 29521683

Group type: EXPERIMENTAL
Intervention: BMI of at least 35 kg/m
Number of subjects: 11886

Group type: COMPARATOR
Intervention: BMI categories (overall, nonaggressive, aggressive prostate cancer including all Gleason 7 cases)
Number of subjects: 11886
Study: 28929560

Group type: EXPERIMENTAL
Intervention: Minocycline (10 mg/kg intravenous)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26518774

Group type: EXPERIMENTAL
Intervention: Housing First plus Assertive Community Treatment
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Housing first plus intensive case management
Number of subjects: 497

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 497
Study: 25136552

Group type: EXPERIMENTAL
Intervention: Tradamix TX1000 (alga Ecklonia bicyclis, Tribulus terrestris, glucosamine oligosaccharide)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Tradamix TX1000
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 22235821

Group type: EXPERIMENTAL
Intervention: Furosemide (60 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination of furosemide and hydrochlorothiazide
Number of subjects: 23
Study: 20178212

Group type: EXPERIMENTAL
Intervention: Clearfil‐SE (self‐etch, water‐based) at 5.0 cm water pressure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clearfil‐SE (self‐etch, water‐based) at 15.0 cm water pressure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: One‐Step Plus (total‐etch, acetone‐based) at 5.0 cm water pressure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: One‐Step Plus (total‐etch, acetone‐based) at 15.0 cm water pressure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PQ1 (total‐etch, ethanol‐based) at 0.0, 5.0, and 15.0 cm water pressure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Peak‐SE (self‐etch, ethanol‐based) at 0.0, 5.0, and 15.0 cm water pressure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clearfil‐SE (self‐etch, water‐based) at 0.0 cm water pressure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: One‐Step Plus (total‐etch, acetone‐based) at 0.0 cm water pressure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Peak‐SE (self‐etch, ethanol‐based) at 0.0 cm water pressure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PQ1 (total‐etch, ethanol‐based) at 0.0 cm water pressure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Peak‐SE (self‐etch, ethanol‐based) at 5.0 cm water pressure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PQ1 (total‐etch, ethanol‐based) at 5.0 cm water pressure
Number of subjects: 24
Study: 17131317

Group type: EXPERIMENTAL
Intervention: H. pylori seropositivity
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: antiCagA antibodies
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Severe chronic atrophic gastritis (SCAG) defined as PGA <22 microg/l
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: CagA seropositivity
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Severe chronic atrophic gastritis (SCAG)
Number of subjects: 1143
Study: 15878384

Group type: EXPERIMENTAL
Intervention: Generic warfarin sodium product
Number of subjects: 35

Group type: COMPARATOR
Intervention: Branded warfarin sodium product
Number of subjects: 35
Study: 12186116

Group type: EXPERIMENTAL
Intervention: Group A (Insulin only, 50 patients)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Group B (Insulin + GBC 20 mg/day, 49 patients)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Group C (Morning insulin + GBC 20 mg/day, 43 patients)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Group D (Evening insulin + GBC 20 mg/day, 46 patients)
Number of subjects: 188
Study: 9875835

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9382910

Group type: EXPERIMENTAL
Intervention: NIDCAP
Number of subjects: 35

Group type: COMPARATOR
Intervention: Routine infant care (Control)
Number of subjects: 35
Study: 1773076

Group type: EXPERIMENTAL
Intervention: Air caloric irrigation at 8 L/min for 45 seconds
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Air caloric irrigation at 8 L/min for 60 seconds
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Air caloric irrigation at 8 L/min for 75 seconds
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Air caloric irrigation at 8 L/min for 10-beat and 10-sec measurements
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard error of measurement for SPV calculations
Number of subjects: 30
Study: 6752558

Group type: EXPERIMENTAL
Intervention: Protocol A: 6‐MP (50 mg/m2) p.o. daily + MTX (20‐30 mg/m2) p.o. weekly
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Protocol B: 6‐MP (50 mg/m2) p.o. daily + MTX (75‐150 mg/m2) i.v. every two weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Protocol C: 6‐MP (50 mg/m2) p.o. daily + alternating 8‐week-courses of four biweekly i.v. injections of MTX (75‐150 mg/m2) and four biweekly i.v. injections of Cyclo (600 mg/m2)
Number of subjects: 58
Study: 31796073

Group type: EXPERIMENTAL
Intervention: Trastuzumab + Neratinib + Paclitaxel
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neratinib-based therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 8-gene signature
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: FCGR3A-158V/F genotype
Number of subjects: 100
Study: 27194364

Group type: EXPERIMENTAL
Intervention: CM (native collagen membranes)
Number of subjects: 19

Group type: COMPARATOR
Intervention: VN (cross-linked collagen membranes)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CM and VN groups
Number of subjects: 19
Study: 26027861

Group type: EXPERIMENTAL
Intervention: 0.2 ml 0.8% Hyaluronic Acid (HA) applied immediately after surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment applied)
Number of subjects: 40
Study: 25030475

Group type: EXPERIMENTAL
Intervention: Difficult auditory distraction
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (silent)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Auditory stimuli responses
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Error rate correlation
Number of subjects: 34
Study: 23044704

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) - 1000 shots at maximal tolerable intensity
Number of subjects: 36

Group type: COMPARATOR
Intervention: Local corticosteroid (CS) injection
Number of subjects: 36
Study: 22169787

Group type: EXPERIMENTAL
Intervention: Rubella vaccination (R-vac)
Number of subjects: 1329

Group type: COMPARATOR
Intervention: Pre-vaccination status
Number of subjects: 1329
Study: 19851160

Group type: EXPERIMENTAL
Intervention: ShotBlocker
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 89

Group type: COMPARATOR
Intervention: Typical care control
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Injection phase
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Postinjection phase
Number of subjects: 89
Study: 17069488

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 685-nm wavelength, output power of 50 mW, energy density of 4 J/cm².
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no laser irradiation).
Number of subjects: 20
Study: 15129420

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 195

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 195
Study: 12790985

Group type: EXPERIMENTAL
Intervention: Stapled mucosectomy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional haemorrhoidectomy
Number of subjects: 35
Study: 11783265

Group type: EXPERIMENTAL
Intervention: Scalp-acupuncture
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (mannitol and furosemide)
Number of subjects: 64
Study: 7928125

Group type: EXPERIMENTAL
Intervention: Culture-specific education program
Number of subjects: 182
Study: 2528969

Group type: EXPERIMENTAL
Intervention: zidovudine 600 mg/day for 18 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: zidovudine 900 mg/day for 9 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: zidovudine 1200 mg/day for 9 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: zidovudine 1200 mg/day or highest tolerated dose at 8-hourly intervals after washout
Number of subjects: 74

Group type: COMPARATOR
Intervention: zidovudine 600 mg/day
Number of subjects: 74

Group type: COMPARATOR
Intervention: zidovudine 900 mg/day
Number of subjects: 74

Group type: COMPARATOR
Intervention: zidovudine 1200 mg/day
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: zidovudine
Number of subjects: 74
Study: 1252882

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole 2 tablets twice daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cephalexin 1 g twice daily
Number of subjects: 100
Study: 30947708

Group type: EXPERIMENTAL
Intervention: Thinking While Moving in English (TWM-E) program
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10
Study: 27982478

Group type: EXPERIMENTAL
Intervention: Genetically-increased risk of T2D
Number of subjects: 34840

Group type: EXPERIMENTAL
Intervention: Genetically-increased fasting glucose
Number of subjects: 34840

Group type: EXPERIMENTAL
Intervention: T2D and fasting glucose effects on lumbar spine BMD
Number of subjects: 34840
Study: 25263498

Group type: EXPERIMENTAL
Intervention: Single dose of ampicillin and metronidazole
Number of subjects: 176

Group type: COMPARATOR
Intervention: Multiple-day regimen of ampicillin/amoxicillin and metronidazole
Number of subjects: 176
Study: 23337557

Group type: EXPERIMENTAL
Intervention: Tai chi/yoga
Number of subjects: 92
Study: 22072853

Group type: EXPERIMENTAL
Intervention: Activated Dimethicone plus water (up to 100 mL)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) plus water (up to 100 mL)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Activated Dimethicone and NAC plus water (up to 100 mL)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Water alone (100 mL)
Number of subjects: 148